FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200134400> ?p ?o ?g. }

• W4200134400 endingPage "114909" @default.
• W4200134400 startingPage "114909" @default.
• W4200134400 abstract "Terminalia mantaly (H. Perrier) and Terminalia superba (Engl. & Diels) are sources of treatment for various diseases, including malaria and/or related symptoms in parts of Southwestern Cameroon. However, there is limited information on the extent of the antiplasmodial potential of their extracts.The present study was designed to investigate the antiplasmodial potential of chromatographic sub fractions (SFs) from promising fractions of Terminalia mantaly (Tm) [TmsbwChl, the chloroform fraction from water extract of Tm, IC50 (μg/mL) PfINDO: 0.56, Pf3D7: 1.12; SI > 357 (HEK/PfINDO) & 178 (HEK/Pf3D7)] and Terminalia superba (Ts) [TsrmEA, the ethyl acetate fraction from methanolic extract of Ts, IC50 (μg/mL) PfINDO: 1.82, Pf3D7: 1.65; SI > 109 (HEK/PfINDO) & 121 (HEK/Pf3D7)] obtained from previous studies. The SFs were tested against Plasmodium falciparum 3D7 (Pf3D7-chloroquine sensitive) and INDO (PfINDO-chloroquine resistant) strains in culture. Also, the phytochemical profile of potent SFs was determined and finally, the inhibition of the asexual blood stages of Plasmodium falciparum by the SFs with the highest promise was assessed.Selected SFs were submitted to a second bio-guided fractionation using silica gel column chromatography. The partial phytochemical composition of potent antiplasmodial SFs was determined using gas chromatography coupled to mass spectrometry (GC-MS). The SYBR Green I-based fluorescence microtiter plate assay was used to monitor the growth of Plasmodium falciparum parasites in culture in the presence or absence of extracts. Microscopy and flow cytometry counting was used to assess the Plasmodium falciparum stage-specific inhibition and post-drug exposure growth suppression by highly potent extracts.Twenty-one of the 39 SFs afforded from TmsbwChl showed activity (IC50: 0.29-4.74 μg/mL) against both Pf3D7 and PfINDO strains. Of note, eight SFs namely, Tm25, Tm28-30, Tm34-36 and Tm38, exerted highly potent antiplasmodial activity (IC50 < 1 μg/mL) with IC50PfINDO: 0.41-0.84 μg/mL and IC50Pf3D7: 0.29-0.68 μg/mL. They also displayed very high selectivity (50 < SIPfINDO, SIPf3D7 > 344) on the two Plasmodial strains. On the other hand, 7 SFs (SFs Ts03, Ts04, Ts06, Ts09, Ts10, Ts12 and Ts13) from TsrmEA showed promising inhibitory potential against both parasite strains (IC50: 2.01-5.14 μg/mL). Sub fraction Tm36 (IC50PfINDO: 0.41 μg/mL, SIPfINDO > 243; IC50Pf3D7: 0.29 μg/mL, SIPf3D7 > 344) showed the highest promise. The GC-MS analysis of the 8 selected SFs led to the identification of 99 phytometabolites, with D-limonene (2), benzaldehyde (12), carvone (13), caryophyllene (35), hexadecanoic acid, methyl ester (74) and 9-octadecenoic acid, methyl ester (82) being the main constituents. Sub fractions Tm28, Tm29, Tm30, Tm36 and Tm38 inhibited all the three intraerythrocytic stages of P. falciparum, with strong potency against ring stage development, merozoite egress and invasion processes.This study has identified highly potent antiplasmodial SFs from Terminalia mantaly with significant activity on the intraerythrocytic development of Plasmodium falciparum. These SFs qualify as promising sources of novel antiplasmodial lead compounds. Further purification and characterization studies are expected to unravel molecular targets in rings and merozoites." @default.
• W4200134400 created "2021-12-31" @default.
• W4200134400 creator A5012226561 @default.
• W4200134400 creator A5012443689 @default.
• W4200134400 creator A5013048745 @default.
• W4200134400 creator A5032000852 @default.
• W4200134400 creator A5043347645 @default.
• W4200134400 creator A5049879730 @default.
• W4200134400 creator A5055846501 @default.
• W4200134400 creator A5064687051 @default.
• W4200134400 creator A5069250338 @default.
• W4200134400 creator A5087870986 @default.
• W4200134400 creator A5090364007 @default.
• W4200134400 date "2022-03-01" @default.
• W4200134400 modified "2023-10-18" @default.
• W4200134400 title "Specific sub fractions from Terminalia mantaly (H. Perrier) extracts potently inhibit Plasmodium falciparum rings, merozoite egress and invasion" @default.
• W4200134400 cites W1601022361 @default.
• W4200134400 cites W1876701072 @default.
• W4200134400 cites W1935711444 @default.
• W4200134400 cites W1969307176 @default.
• W4200134400 cites W1988598700 @default.
• W4200134400 cites W1994781602 @default.
• W4200134400 cites W2000158167 @default.
• W4200134400 cites W2014404880 @default.
• W4200134400 cites W2015833924 @default.
• W4200134400 cites W2020251171 @default.
• W4200134400 cites W2022786242 @default.
• W4200134400 cites W2026017734 @default.
• W4200134400 cites W2033985665 @default.
• W4200134400 cites W2036417252 @default.
• W4200134400 cites W2050966592 @default.
• W4200134400 cites W2069303427 @default.
• W4200134400 cites W2070408555 @default.
• W4200134400 cites W2079098415 @default.
• W4200134400 cites W2085585307 @default.
• W4200134400 cites W2088387917 @default.
• W4200134400 cites W2114818342 @default.
• W4200134400 cites W2114918609 @default.
• W4200134400 cites W2121315016 @default.
• W4200134400 cites W2131185559 @default.
• W4200134400 cites W2138281549 @default.
• W4200134400 cites W2151510498 @default.
• W4200134400 cites W2154313767 @default.
• W4200134400 cites W2159733380 @default.
• W4200134400 cites W2161311583 @default.
• W4200134400 cites W2167960295 @default.
• W4200134400 cites W2169329132 @default.
• W4200134400 cites W2171102256 @default.
• W4200134400 cites W2285256643 @default.
• W4200134400 cites W2395970106 @default.
• W4200134400 cites W2410777859 @default.
• W4200134400 cites W2467614481 @default.
• W4200134400 cites W2512582262 @default.
• W4200134400 cites W2579721738 @default.
• W4200134400 cites W2581893641 @default.
• W4200134400 cites W2586114736 @default.
• W4200134400 cites W2589610307 @default.
• W4200134400 cites W2589615913 @default.
• W4200134400 cites W2597604035 @default.
• W4200134400 cites W2610742544 @default.
• W4200134400 cites W2767071503 @default.
• W4200134400 cites W2776821722 @default.
• W4200134400 cites W2785580808 @default.
• W4200134400 cites W2793059322 @default.
• W4200134400 cites W2799529229 @default.
• W4200134400 cites W2802394482 @default.
• W4200134400 cites W2809308998 @default.
• W4200134400 cites W2938448257 @default.
• W4200134400 cites W2942648928 @default.
• W4200134400 cites W2966802359 @default.
• W4200134400 cites W2992626227 @default.
• W4200134400 cites W2997259877 @default.
• W4200134400 cites W3037788029 @default.
• W4200134400 cites W3047692633 @default.
• W4200134400 cites W3190648404 @default.
• W4200134400 cites W3196592973 @default.
• W4200134400 doi "https://doi.org/10.1016/j.jep.2021.114909" @default.
• W4200134400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34902534" @default.
• W4200134400 hasPublicationYear "2022" @default.
• W4200134400 type Work @default.
• W4200134400 citedByCount "1" @default.
• W4200134400 countsByYear W42001344002022 @default.
• W4200134400 crossrefType "journal-article" @default.
• W4200134400 hasAuthorship W4200134400A5012226561 @default.
• W4200134400 hasAuthorship W4200134400A5012443689 @default.
• W4200134400 hasAuthorship W4200134400A5013048745 @default.
• W4200134400 hasAuthorship W4200134400A5032000852 @default.
• W4200134400 hasAuthorship W4200134400A5043347645 @default.
• W4200134400 hasAuthorship W4200134400A5049879730 @default.
• W4200134400 hasAuthorship W4200134400A5055846501 @default.
• W4200134400 hasAuthorship W4200134400A5064687051 @default.
• W4200134400 hasAuthorship W4200134400A5069250338 @default.
• W4200134400 hasAuthorship W4200134400A5087870986 @default.
• W4200134400 hasAuthorship W4200134400A5090364007 @default.
• W4200134400 hasConcept C185592680 @default.
• W4200134400 hasConcept C195475562 @default.
• W4200134400 hasConcept C203014093 @default.
• W4200134400 hasConcept C2778048844 @default.

• next